Table 2.
Demographic, anthropometric, and biochemical characteristics.
| T2Ds (n = 247) | |
|---|---|
| Demographics | |
| Age, years | 51.8 ± 11.9 |
| Male, n (%) | 136 (55) |
| Female, n (%) | 112 (45) |
| Ethinicity | |
| Caucasian, n (%) | 155 (63) |
| Black or other minority ethnicity, n (%) | 92 (37) |
| Anthropometrics | |
| Height, cm | 168 ± 10 |
| Weight, kg | 96.9 ± 19.1 |
| Body mass index, kg/m2 | 34.2 ± 6.0 |
| Systolic BP, mmHg | 138 ± 16 |
| Diastolic BP, mmHg | 87 ± 8 |
| Heart rate, beats/min | 76 ± 12 |
| Medical history | |
| Diabetes duration, months | 61 (32–120) |
| Never smoked, n (%) | 140 (56) |
| Ex-smoker, n (%) | 68 (28) |
| Current smoker, n (%) | 39 (16) |
| Hypertension, n (%) | 121 (49) |
| Dyslipidaemia, n (%) | 148 (60) |
| Medications | |
| ACE inhibitor, n (%) | 67 (27) |
| ARB, n (%) | 28 (11) |
| Beta blocker, n (%) | 16 (6) |
| Calcium channel blocker, n (%) | 50 (20) |
| Statin, n (%) | 144 (58) |
| Metformin, n (%) | 214 (87) |
| Sulfonylurea, n (%) | 50 (20) |
| DPP-IV inhibitor, n (%) | 16 (6) |
| SGLT2 inhibitor, n (%) | 36 (15) |
| GLP-1 receptor agonist, n (%) | 17 (7) |
| Insulin, n (%) | 20 (8) |
| Fasting blood tests | |
| Creatinine, mmol/l | 74 ± 16 |
| Estimated GFR, ml/min | 84 ± 10 |
| Glucose, mmol/l | 7.7 (6.7–9.5) |
| HbA1c, % | 7.4 ± 1.1 |
| HbA1c, mmol/mol | 57 ± 12 |
| LDL cholesterol, mmol/l | 2.4 ± 0.8 |
Data are n (%), mean ± SD, or median (IQR).
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; DPP-IV, dipeptidyl peptidase-IV; GFR, glomerular filtration rate; GLP-1, glucagon-like peptide-1; IQR, interquartile range; LDL, low-density lipoprotein; SGLT2, sodium glucose co-transporter 2.